UT-XLEAR
16.5.2022 16:02:14 CEST | Business Wire | Press release
Today Xlear announced a new partnership with Dr. Ferrer BioPharma (DFBP), which will make Xlear nasal spray the first nasal hygiene tool to deploy the GentleMist nozzle—the next generation nasal spray technology that research shows achieves better compound dispersion and coverage and a better user experience.
Nasal cleansing studies have found that rinsing the nose and nasal cavity is an important tool for improving health and wellbeing. Numerous clinical and lab studies have found that nasal hygiene is an important adjunct in countering rhinositus, as well as a range of bacterial and viral infections.
New research, published by The European Society of Medicine found that the GentleMist nozzle achieved more uniform and more complete dispersion of nasal sprays into the nose and nasal cavity. The study also found that the new nozzle was gentler and significantly improved the user experience over typical nose spray technologies. You can read the full study by clicking here: Evaluation of Patient Experience for a Computationally-Guided Intranasal Spray Protocol to Augment Therapeutic Penetration: Implications for Effective Treatments for COVID-19, Rhinitis, and Sinusitis | Medical Research Archives (esmed.org)
Traditionally nasal sprays have just had a standard pattern where the spray shoots straight up the airway in the direction it is sprayed. The new nozzle is very gentle and the spray is applied in a vortex/whirlpool pattern. This is extremely important and beneficial for Xlear and their customers as it allows Xlear’s mix (saline, xylitol and grapefruit seed extract) to be applied much more effectively and completely to the nose and nasal cavity.
“For more than twenty years, millions of people have been using and benefiting from our nasal spray and we are extremely excited to make this new technology available to them to improve their user experience. We realize that if washing our nose every morning and evening is uncomfortable, or irritating or hurts in even the slightest way we are not going to have people wash their nose enough to where it will make a difference. If it hurt us every time we washed our hands…or brushed our teeth, we wouldn’t be doing that enough either. Just like washing our hands, taking a shower and brushing our teeth, washing our nose is an added layer of protection to keeping us clean and healthy…and breathing better all day,” said Xlear CEO Nate Jones.
Xlear is not intended to diagnose, treat, cure or prevent any disease.
About Xlear
Founded in 2000, Xlear, Inc. is recognized as the leading manufacturer of natural, proactive health care products with xylitol. Xlear is committed to providing consumers with the highest quality products while striving to educate medical and dental professionals, as well their patients, about how using xylitol instead of sugar can help people live a much healthier and happy life. Xlear is supported by a team of doctors, hygienists and scientists who advocate the use and benefits of xylitol through continuous clinical research. Xlear, Inc. offers Xlear Nasal Spray, an award-winning, patented saline and xylitol nasal solution; a complete line of oral health products offered under the Spry Dental Defense System; and Lite&Sweet, a xylitol and erythritol sweetener used as a sugar substitute in cooking, baking and general consumption. For more information visit www.xlear.com .
About Dr. Ferrer BioPharma
Dr. Ferrer BioPharma are the leading innovators in intranasal medications to treat cough, colds, flu, and allergies. Dr. Ferrer BioPharma uses advanced nanoparticle technology to bring high-quality, evidence-based, consumer-focused, and doctor-invented products to the market. The mission is to provide to the market evidence-based therapies combining new ideas with proven concepts in the service of helping people. From molecules to the delivery of effective therapies to treat the populations we serve, Dr. Ferrer Biopharma is designing top-of-the-line intranasal treatments to help people breathe better. For more information visit www.drferrerbiopharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005266/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom